Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy

被引：2

作者：

Carreau, Nicole A. ^{[1
]}

Pail, Orrin ^{[1
]}

Armand, Philippe ^{[2
]}

Merryman, Reid W. ^{[3
]}

Advani, Ranjana H. ^{[4
]}

Spinner, Michael A. ^{[5
]}

Herrera, Alex F. ^{[6
]}

Chen, Robert W. ^{[6
]}

Tomassetti, Sarah ^{[7
]}

Ramchandren, Radhakrishnan ^{[8
]}

Hamid, Muhammad ^{[9
]}

Assouline, Sarit ^{[10
]}

Santiago, Raoul ^{[10
]}

Wagner-Johnston, Nina D. ^{[11
]}

Paul, Suman ^{[12
]}

Svoboda, Jakub ^{[13
]}

Bair, Steven M. ^{[14
]}

Barta, Stefan Klaus ^{[15
]}

Liu, Yang ^{[16
]}

Nathan, Sunita ^{[17
]}

Burkart, Madelyn ^{[18
]}

Karmali, Reem ^{[19
]}

Torka, Pallawi ^{[20
]}

David, Kevin A. ^{[21
]}

Wei, Catherine ^{[21
]}

Lansigan, Frederick ^{[22
]}

Emery, Lukas ^{[22
]}

Persky, Daniel ^{[23
]}

Smith, Sonali M. ^{[24
]}

Chavez, Julio C. ^{[25
]}

Xia, Yuhe ^{[26
]}

Troxel, Andrea B. ^{[26
]}

Diefenbach, Catherine ^{[27
]}

机构：

[1] NYU Langone Hlth, New York, NY USA

[2] Dana Farber Canc Inst, Boston, MA 02115 USA

[3] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[4] Stanford Univ, Dept Med, Div Oncol, Stanford, CA 94305 USA

[5] Stanford Univ, Stanford, CA 94305 USA

[6] City Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Duarte, CA USA

[7] City Hope Natl Med Ctr, Duarte, CA USA

[8] Karmanos Canc Inst, Dept Oncol, Detroit, MI USA

[9] Karmanos Canc Inst, Detroit, MI USA

[10] McGill Univ, Montreal, PQ, Canada

[11] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[12] Johns Hopkins Univ, Baltimore, MD USA

[13] Hosp Univ Penn, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA

[14] Hosp Univ Penn, Abramson Canc Ctr, 3400 Spruce St, Philadelphia, PA 19104 USA

[15] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[16] Fox Chase Canc Ctr, Dept Hematol Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[17] Rush Univ, Med Ctr, Chicago, IL 60612 USA

[18] Northwestern Univ, Chicago, IL 60611 USA

[19] Northwestern Univ, Div Hematol, Chicago, IL 60611 USA

[20] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA

[21] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA

[22] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA

[23] Univ Arizona, Ctr Canc, Div Hematol Oncol, Tucson, AZ USA

[24] Univ Chicago Med, Chicago, IL USA

[25] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[26] NYU, Sch Med, New York, NY USA

[27] NYU, Sch Med, Inst Canc, New York, NY USA

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-117448

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[1] Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy
Carreau, Nicole A.
Pail, Orrin
Armand, Philippe
Merryman, Reid
Advani, Ranjana H.
Spinner, Michael A.
Herrera, Alex
Chen, Robert
Tomassetti, Sarah
Ramchandren, Radhakrishnan
Hamid, Muhammad S.
Assouline, Sarit
Santiago, Raoul
Wagner-Johnston, Nina
Paul, Suman
Svoboda, Jakub
Bair, Steven
Barta, Stefan
Liu, Yang
Nathan, Sunita
Karmali, Reem
Burkart, Madelyn
Torka, Pallawi
David, Kevin
Wei, Catherine
Lansigan, Frederick
Emery, Lukas
Persky, Daniel
Smith, Sonali
Godfrey, James
Chavez, Julio
Xia, Yuhe
Troxel, Andrea B.
Diefenbach, Catherine
[J]. ONCOLOGIST, 2020, 25 (10): : 878 - 885
[2] Therapy of indolent non-Hodgkin lymphoma
Seiler, T.
Herfarth, K.
Klapper, W.
Dreyling, M.
[J]. ONKOLOGE, 2014, 20 (10): : 1028 - 1038
[3] Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy
Carreau, Nicole A.
Armand, Philippe
Merryman, Reid W.
Advani, Ranjana H.
Spinner, Michael A.
Herrera, Alex F.
Ramchandren, Radhakrishnan
Hamid, Muhammad S.
Assouline, Sarit
Santiago, Raoul
Wagner-Johnston, Nina
Paul, Suman
Svoboda, Jakub
Bair, Steven M.
Barta, Stefan K.
Nathan, Sunita
Karmali, Reem
Torka, Pallawi
David, Kevin
Lansigan, Frederick
Persky, Daniel
Godfrey, James
Chavez, Julio C.
Xia, Yuhe
Diefenbach, Catherine
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2020, 191 (01) : 44 - 51
[4] Is it time to rethink checkpoint blockade therapy in non-Hodgkin lymphoma?
Phillips, Elizabeth H.
Illidge, Tim M.
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2020, 191 (01) : 13 - 14
[5] Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma
Merryman, Reid W.
Armand, Philippe
Wright, Kyle T.
Rodig, Scott J.
[J]. BLOOD ADVANCES, 2017, 1 (26) : 2643 - 2654
[6] Rituximab therapy for indolent non-Hodgkin's lymphoma
Hagenbeek, A
Czuczman, MS
Ghielmini, M
Herold, M
Kimby, E
Solal-Céligny, P
Unterhalt, M
[J]. ANTI-CANCER DRUGS, 2002, 13 : S11 - S17
[7] Current approaches to therapy for indolent non-Hodgkin's lymphoma
Cheson, BD
[J]. ONCOLOGY-NEW YORK, 1998, 12 (10): : 25 - 34
[8] Therapy strategies for aggressive non-Hodgkin's lymphoma
Held, G.
Wulf, G.
[J]. ONKOLOGE, 2015, 21 (10): : 946 - 952
[9] Secondary malignancies after therapy of indolent non-Hodgkin's lymphoma
Friedberg, Jonathan W.
[J]. HAEMATOLOGICA, 2008, 93 (03) : 336 - 338
[10] Therapy for stage I aggressive non-Hodgkin's lymphoma
Kluin-Nelemans, HC
[J]. CROATIAN MEDICAL JOURNAL, 2002, 43 (05) : 546 - 549

← 1 2 3 4 5 →